retatrutide nonalcoholic steatohepatitis trial A Placebo-Controlled of Subcutaneous Semaglutide in retatrutide nonalcoholic fatty liver disease

Discontinuation rates were higher than those for the current weekly injections, partly because some people lost more weight than they intended

Our model projects that the lower average BMI for insured groups has more impact than the increased ability to access the drugs, and so the overall mortality and morbidity impact is typically lower than for the general population

3.67 times higher risk of gastroparesis , or stomach paralysis, which limits the passage of food from the stomach to the small intestine and results in symptoms like vomiting, nausea and abdominal pain

Cisapride, a previously used prokinetic drug, has been withdrawn from the market because of concerns about cardiac arrhythmias